← Back to All US Stocks

VASO Corp (VASO) Stock Fundamental Analysis & AI Rating 2026

VASO OTC Electromedical & Electrotherapeutic Apparatus DE CIK: 0000839087
Recently Updated • Analysis: Apr 18, 2026 • SEC Data: 2025-12-31
HOLD
72% Conf
Pending
Analysis scheduled

📊 VASO Key Takeaways

Revenue: $89.1M
Net Margin: 1.8%
Free Cash Flow: $8.7M
Current Ratio: 1.59x
Debt/Equity: 0.00x
EPS: $0.01
AI Rating: HOLD with 72% confidence
VASO Corp (VASO) receives a HOLD rating with 72% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $89.1M, net profit margin of 1.8%, and return on equity (ROE) of 5.3%, VASO Corp demonstrates mixed fundamentals in the Healthcare sector. Below is our complete VASO stock analysis for 2026.

Is VASO Corp (VASO) a Good Investment?

Claude

VASO Corp maintains a fortress balance sheet with 35M cash and negligible debt, supporting positive 8.7M free cash flow despite operating losses. However, severe operational inefficiency—evidenced by -3.2% operating margin despite 61.4% gross margin—combined with minimal 2.7% revenue growth and share dilution suggests fundamental business restructuring is needed before the balance sheet strength can translate into shareholder value.

Why Buy VASO Corp Stock? VASO Key Strengths

Claude
  • + Strong 61.4% gross margin demonstrates competitive product positioning and pricing power in electromedical apparatus market
  • + Fortress balance sheet with 35M cash (39.6% of total assets), 1.59x current ratio, and negligible debt (15K long-term) providing substantial financial flexibility and downside protection
  • + Positive 8.7M free cash flow generation despite operating loss indicates underlying cash-generative capability despite operational challenges

VASO Stock Risks: VASO Corp Investment Risks

Claude
  • ! Severe operational inefficiency with 64.7% operating expense ratio despite 61.4% gross margin, creating structural -3.2% operating margin and indicating fundamental cost control failures
  • ! Minimal 2.7% YoY revenue growth with only 1.8% net margin leaves minimal room for error and suggests limited competitive advantages or market expansion
  • ! Share dilution evident from flat EPS (0% YoY) despite 65% net income growth indicates value destruction through dilutive capital raises and excessive share count

Key Metrics to Watch

Claude
  • * Operating margin trend and SG&A expense reduction initiatives to narrow 57.6M gap between gross profit and operating loss
  • * Revenue growth acceleration and product pipeline success in specialty electromedical segments
  • * Share dilution rate trajectory and insider buying activity as confidence indicator for operational turnaround

VASO Corp (VASO) Financial Metrics & Key Ratios

Revenue
$89.1M
Net Income
$1.6M
EPS (Diluted)
$0.01
Free Cash Flow
$8.7M
Total Assets
$88.3M
Cash Position
$35.1M

💡 AI Analyst Insight

VASO Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

VASO Profit Margin, ROE & Profitability Analysis

Gross Margin 61.4%
Operating Margin -3.2%
Net Margin 1.8%
ROE 5.3%
ROA 1.8%
FCF Margin 9.8%

VASO vs Healthcare Sector: How VASO Corp Compares

How VASO Corp compares to Healthcare sector averages

Net Margin
VASO 1.8%
vs
Sector Avg 12.0%
VASO Sector
ROE
VASO 5.3%
vs
Sector Avg 15.0%
VASO Sector
Current Ratio
VASO 1.6x
vs
Sector Avg 2.0x
VASO Sector
Debt/Equity
VASO 0.0x
vs
Sector Avg 0.6x
VASO Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is VASO Corp Stock Overvalued? VASO Valuation Analysis 2026

Based on fundamental analysis, VASO Corp has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
5.3%
Sector avg: 15%
Net Profit Margin
1.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

VASO Corp Balance Sheet: VASO Debt, Cash & Liquidity

Current Ratio
1.59x
Quick Ratio
1.57x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
$15.0K

VASO Revenue & Earnings Growth: 5-Year Financial Trend

VASO 5-year financial data: Year 2018: Revenue $74.0M, Net Income N/A, EPS N/A. Year 2019: Revenue $75.7M, Net Income N/A, EPS $-0.02. Year 2020: Revenue $75.5M, Net Income N/A, EPS $0.00. Year 2021: Revenue $75.6M, Net Income $358.0K, EPS N/A.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: VASO Corp's revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $0.01 reflects profitable operations.

VASO Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
9.8%
Free cash flow / Revenue

VASO Quarterly Earnings & Performance

Quarterly financial performance data for VASO Corp including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2024 $19.4M $454.0K $0.01
Q2 2024 $20.2M -$18.0K $0.00
Q1 2022 $16.5M -$344.0K N/A
Q3 2021 $17.4M -$643.0K N/A
Q2 2021 $16.1M -$643.0K N/A
Q1 2021 $16.5M -$643.0K N/A
Q3 2020 $17.5M $562.0K $0.00
Q2 2020 $16.3M -$597.0K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

VASO Corp Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$9.3M
Cash generated from operations
Capital Expenditures
$566.0K
Investment in assets
Dividends
None
No dividend program

VASO SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for VASO Corp (CIK: 0000839087)

📋 Recent SEC Filings

Date Form Document Action
Mar 31, 2026 10-K ea0281952-10k_vasocorp.htm View →
Feb 12, 2026 8-K ea0276822-8k_vaso.htm View →
Dec 19, 2025 8-K ea0270345-8k_vaso.htm View →
Nov 20, 2025 8-K ea0266535-8k_vaso.htm View →
Nov 14, 2025 10-Q ea0264357-10q_vaso.htm View →

Frequently Asked Questions about VASO

What is the AI rating for VASO?

VASO Corp (VASO) has an AI rating of HOLD with 72% confidence, based on fundamental analysis of SEC EDGAR filings.

What are VASO's key strengths?

Claude: Strong 61.4% gross margin demonstrates competitive product positioning and pricing power in electromedical apparatus market. Fortress balance sheet with 35M cash (39.6% of total assets), 1.59x current ratio, and negligible debt (15K long-term) providing substantial financial flexibility and downside protection.

What are the risks of investing in VASO?

Claude: Severe operational inefficiency with 64.7% operating expense ratio despite 61.4% gross margin, creating structural -3.2% operating margin and indicating fundamental cost control failures. Minimal 2.7% YoY revenue growth with only 1.8% net margin leaves minimal room for error and suggests limited competitive advantages or market expansion.

What is VASO's revenue and growth?

VASO Corp reported revenue of $89.1M.

Does VASO pay dividends?

VASO Corp does not currently pay dividends.

Where can I find VASO SEC filings?

Official SEC filings for VASO Corp (CIK: 0000839087) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is VASO's EPS?

VASO Corp has a diluted EPS of $0.01.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is VASO a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, VASO Corp has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is VASO stock overvalued or undervalued?

Valuation metrics for VASO: ROE of 5.3% (sector avg: 15%), net margin of 1.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy VASO stock in 2026?

Our dual AI analysis gives VASO Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is VASO's free cash flow?

VASO Corp's operating cash flow is $9.3M, with capital expenditures of $566.0K. FCF margin is 9.8%.

How does VASO compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 1.8% (avg: 12%), ROE 5.3% (avg: 15%), current ratio 1.59 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 18, 2026 | Data as of: 2025-12-31 | Powered by Claude AI